Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dance class may ease Parkinson's 'OFF-Time' and boost brain power

NCT ID NCT04122690

Symptom relief Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether partnered dance aerobic exercise can reduce 'OFF-time' (when Parkinson's medication stops working well) and improve thinking skills. Researchers will enroll 82 people with Parkinson's who experience OFF-time. Participants will take dance classes twice a week, and the study will measure changes in movement, cognition, and brain iron levels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

82 people

The number who actually took part.

Started

Jan 2021

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 89 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age: older than 40 years (40 is upper limit for young onset PD) * Montreal Cognitive Assessment (MoCA) score \>17 * Able to walk with or without an assistive device at least 10 feet * Best corrected/aided acuity better than 20/70 in the better eye * Willingness to be randomized to either group * H\&Y stages I-III * Report OFF times (reporting \>0 on item 4.3 of the UPDRS-IV) * Show clear symptomatic benefit from antiparkinsonian medications * e.g., alleviated rigidity, bradykinesia, and tremor * Fluent in English to comprehend and participate Exclusion Criteria: * Untreated Major Depression and major psychiatric illness * History of stroke, or traumatic brain injury * Pure-tone threshold average sensitivity at 0.5, 1.0, and 2.0 kHz exceeds 40 dB * Previous participation in PDAE or WAE classes. * Alcohol abuse and/or use of antipsychotics * Lives outside of the study site or is planning to move out of the area in next year or leave the area for \>1 month during the next year * Taking moderate to high doses of beta-blockers with a resting heart rate below 60 beats/min since exercise intensity is measured through target heart rate. * Severe cardiac disease, including: * New York Heart Association (NYHA) Class III or IV congestive heart failure * clinically significant aortic stenosis * history of cardiac arrest, use of a cardiac defibrillator * uncontrolled angina * as discussed we are not planning to perform routine exercise tolerance tests prior to enrollment * Other significant co-morbid disease that would impair ability to participate in the exercise-based intervention * e.g. renal failure on hemodialysis, excessive alcohol use (\>14 drinks per wk) * Any contraindications to MRI eg claustrophobia, etc

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognition are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cognitive disorder Motor Activity Nerve Degeneration Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cognition Exercise therapy Parkinson's disease

Contacts and locations

Locations

  • Atlanta VA Medical and Rehab Center, Decatur, GA

    Decatur, Georgia, 30033-4004, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.